SCHEMBL4714080

SCHEMBL4714080

O=C(O)c1ccc(Cl)c(NC(=O)c2ccccc2Cl)c1

nearest known ligand 0.68

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.68
PPARG P37231 1/20 0.67
NR1H4 Q96RI1 1/20 0.67
CYP1A2 P05177 1/20 0.66
HPGD P15428 1/20 0.66
CYP2C19 P33261 1/20 0.66
PYGL P06737 2/20 0.63
HDAC8 Q9BY41 5/20 0.59
HDAC6 Q9UBN7 5/20 0.59
HDAC1 Q13547 4/20 0.58
ALDH1A1 P00352 3/20 0.57
LMNA P02545 1/20 0.57
SMO Q99835 1/20 0.55
KMT2A Q03164 2/20 0.55
RAB9A P51151 1/20 0.55
KCNK3 O14649 1/20 0.55
KCNK9 Q9NPC2 1/20 0.55
SLC16A3 O15427 1/20 0.54
MEN1 O00255 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16127883 0.91 PPARG (0.67) MAPTPPARGNR1H4CYP1A2HPGD
SCHEMBL4700752 0.89 PYGL (0.81) MAPTPPARGNR1H4CYP1A2HPGD
SCHEMBL4716458 0.84 ALDH1A1 (0.69) MAPTPPARGNR1H4CYP1A2HPGD
SCHEMBL10238371 0.81 MAPT (1.00) MAPTPPARGNR1H4CYP1A2HPGD
SCHEMBL17538586 0.81 CREBBP (0.64) MAPTPPARGNR1H4HPGDHDAC8
SCHEMBL20601662 0.81 PYGL (0.82) MAPTCYP1A2CYP2C19PYGLHDAC8
SCHEMBL15668350 0.80 CYP1A2 (0.68) MAPTCYP1A2HPGDCYP2C19ALDH1A1
SCHEMBL15936047 0.80 MEN1 (0.59) MAPTPPARGNR1H4CYP1A2HDAC8
SCHEMBL1307862 0.80 MEN1 (0.79) MAPTPPARGNR1H4HDAC8HDAC6
SCHEMBL4254327 0.80 SMO (0.79) MAPTSMOKMT2ARAB9AKCNK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1877401-A2 NOVEL COMPOUNDS USEFUL FOR BRADYKININ B1 RECEPTOR ANTAGONISM Elan Pharmaceuticals Inc. (US) 2008-01-16 EP disclosed
US-20070032475-A1 Novel compounds useful for bradykinin B1 receptor antagonism ELAN PHARMACEUTICALS, INC. 2007-02-08 US disclosed
US-20070032475-A1 Novel compounds useful for bradykinin B1 receptor antagonism ELAN PHARMACEUTICALS, INC. 2007-02-08 US disclosed
US-20070032475-A1 Novel compounds useful for bradykinin B1 receptor antagonism ELAN PHARMACEUTICALS, INC. 2007-02-08 US disclosed
WO-2006113140-A2 NOVEL COMPOUNDS USEFUL FOR BRADYKININ B1 RECEPTOR ANTAGONISM ELAN PHARMACEUTICALS, INC. (US) 2006-10-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070032475-A1 Novel compounds useful for bradykinin B1 receptor antagonism BDKRB1, BDKRB2, NPBWR1 MAPT 3303/4885PPARG 3739/4885NR1H4 304/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.